AZD9291 in
AZD9291 in
About this item
Full title
AZD9291 in
Author / Creator
Publisher
Future Medicine Ltd
Journal title
Future oncology (London, England), 2015-11, Vol.11 (22), p.3069-3081
Language
English
Formats
Publication information
Publisher
Future Medicine Ltd
Subjects
More information
Scope and Contents
Contents
Non-small-cell lung cancer (NSCLC) patients whose tumors have an
-activating mutation develop acquired resistance after a median of 9-11 months from the beginning of treatment with erlotinib, gefitinib and afatinib. T790M mutation is the cause of this resistance in approximately 60% of cases. AZD9291 is an oral, irreversible, mutant-selective EG...
Alternative Titles
Full title
AZD9291 in
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_futurescience_futuremedicine_10_2217_fon_15_250
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_futurescience_futuremedicine_10_2217_fon_15_250
Other Identifiers
ISSN
1479-6694
E-ISSN
1744-8301
DOI
10.2217/fon.15.250
How to access this item
Log in as a Library member
